当前位置： SCI文献检索 > Cardiovascular Therapeutics期刊下所有文献 > Risk factors for intracranial hemorrhage during vitamin K antagonist therapy in patients with nonvalvular atrial fibrillation: A case-control study.

Risk factors for intracranial hemorrhage during vitamin K antagonist therapy in patients with nonvalvular atrial fibrillation: A case-control study.

Abstract：

BACKGROUND:Intracranial hemorrhage (ICH) is the most fearful side effect of oral anticoagulant therapy. It is still unclear which risk factor is involved in ICH during vitamin K antagonists (VKAs) treatment and if commonly used bleeding risk scores are able to predict ICH. PURPOSE:Search for individual risk factors and bleeding risk scores (HAS-BLED, ATRIA and ORBIT) associated with ICHs in patients with atrial fibrillation treated with VKAs. METHODS:This is a retrospective case-control study in a single Thrombosis Center. During a 7-year period, patients with nonvalvular atrial fibrillation (NVAF) who developed ICH during VKAs were identified as cases. Four control patients matched for gender, age and length of VKAs were assigned to each case. The association between considered risk factors and ICHs was evaluated using a linear logistic regression method and expressed as odds ratio. Receiver operator characteristic (ROC) curves to assess the predictive ability of bleeding risk scores HAS-BLED, ATRIA and ORBIT were also evaluated. RESULTS:Fifty-one cases of ICH, most of whom were 80 years of age or older (72.5%), were retrieved from the Thrombosis Center's database. Compared to 204 controls, no individual risk factors were associated with ICH. Poor ability to predict ICH was also found using ROC curves (C-statistic for HAS-BLED, ATRIA, and ORBIT were 0.55, 0.53 and 0.54, respectively). CONCLUSIONS:ICHs during VKA therapy preferentially occur in very elderly patients. The risk of ICH is not predicted by the commonly used risk scores.

journal_name

Cardiovasc Ther

journal_title

Cardiovascular therapeutics

authors

Zanella L,Zoppellaro G,Marigo L,Denas G,Padayattil Jose S,Pengo V

doi

10.1111/1755-5922.12458

subject

Has Abstract

pub_date

2018-10-01 00:00:00

pages

e12458

issue

5

eissn

1755-5914

issn

1755-5922

journal_volume

36

pub_type

杂志文章

相关文献

Cardiovascular Therapeutics文献大全
  • Effect on mode of death of heart failure treatment started with bisoprolol followed by Enalapril, compared to the opposite order: results of the randomized CIBIS III trial.

    abstract：BACKGROUND:Mode of death in chronic heart failure (CHF) may be of relevance to choice of therapy for this condition. Sudden death is particularly common in patients with early and/or mild/moderate CHF. β-Blockade may provide better protection against sudden death than ACE inhibition (ACEI) in this setting. METHODS:We ...

    journal_title：Cardiovascular therapeutics

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1111/j.1755-5922.2010.00185.x

    authors： Krum H,van Veldhuisen DJ,Funck-Brentano C,Vanoli E,Silke B,Erdmann E,Follath F,Ponikowski P,Goulder M,Meyer W,Lechat P,Willenheimer R,behalf of the CIBIS III Investigators.

    更新日期：2011-04-01 00:00:00

  • Impact on survival of warfarin in patients with pulmonary arterial hypertension receiving subcutaneous treprostinil.

    abstract：INTRODUCTION:Anticoagulation is a common treatment modality in patients with pulmonary arterial hypertension (PAH). Further studies are needed to appropriately assess the risk/benefit ratio of anticoagulation, particularly in PAH patients receiving PAH-specific therapies. AIMS:We use observational long-term data on PA...

    journal_title：Cardiovascular therapeutics

    pub_type： 杂志文章

    doi：10.1111/1755-5922.12281

    authors： Ascha M,Zhou X,Rao Y,Minai OA,Tonelli AR

    更新日期：2017-10-01 00:00:00

  • Prescribers' practice of assessing arrhythmia risk with QT-prolonging medications.

    abstract：AIMS:This study aimed to assess prescribers' monitoring for arrhythmic risk with QT-prolonging medications (LQT drugs). METHODS:Over a 6-month period, all inpatients under the care of Cardiologists (Cohort A) and General Physicians (Cohort B) at Aberdeen Royal Infirmary who were prescribed drugs with known risk of Tor...

    journal_title：Cardiovascular therapeutics

    pub_type： 杂志文章

    doi：10.1111/1755-5922.12085

    authors： Choo WK,Turpie D,Milne K,Davidson L,Elofuke P,Whitfield J,Broadhurst P

    更新日期：2014-10-01 00:00:00

  • Clinical effectiveness and safety of antazoline-based therapy in patients with stable coronary artery disease undergoing pharmacological cardioversion of short-duration atrial fibrillation in the emergency department.

    abstract：INTRODUCTION:Options for a pharmacological cardioversion (CV) of short-duration atrial fibrillation (AF) in patients with a stable coronary artery disease (CAD) are limited to amiodarone or vernakalant. Antazoline has been reported to achieve high rates of AF conversion to sinus rhythm, but data on its effectiveness an...

    journal_title：Cardiovascular therapeutics

    pub_type： 杂志文章

    doi：10.1111/1755-5922.12469

    authors： Farkowski MM,Maciag A,Zurawska M,Kowalik I,Szwed H,Pytkowski M

    更新日期：2018-12-01 00:00:00

  • The Total Incidence of Complications and the Impact of an Anticoagulation Regime on Adverse Events After Cryoballoon Ablation of Atrial Fibrillation: A Single-Center Study of 409 Patients.

    abstract：AIM:Data evaluating the complications of pulmonary vein isolation (PVI) using second-generation cryoballoons (CB) related to different anticoagulation regimes are limited. This study evaluates the total complications and the impact of novel oral anticoagulants (NOACs) compared to phenprocoumon on adverse events in the ...

    journal_title：Cardiovascular therapeutics

    pub_type： 杂志文章

    doi：10.1111/1755-5922.12178

    authors： Koektuerk B,Turan CH,Yorgun H,Keskin K,Schoett M,Dahmen A,Gorr E,Yang A,Hoppe C,Horlitz M,Turan RG

    更新日期：2016-06-01 00:00:00

  • Microsomal transfer protein inhibitors, new approach for treatment of familial hypercholesterolemia, review of the literature, original findings, and clinical significance.

    abstract：:The genetic causes of cholesterol metabolism disorders usually lead to premature atherosclerosis. The most well recognized genetically caused hypercholesterolemia is familial hypercholesterolemia. Although the disease is well known, as the discovery of low-density lipoprotein receptor, the classical treatment with lip...

    journal_title：Cardiovascular therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/1755-5922.12105

    authors： Kolovou G,Vasiliadis I,Gontoras N,Kolovou V,Hatzigeorgiou G

    更新日期：2015-04-01 00:00:00

  • Obstacles to mineralocorticoid receptor antagonists in a community-based heart failure population.

    abstract：AIM:Previous studies and national assessments indicate an undertreatment of mineralocorticoid receptor antagonists (MRA) in heart failure with reduced ejection fraction (HFrEF). This study aimed to investigate why MRA is not used to full extent. METHODS:A complete community-based heart failure population was studied. ...

    journal_title：Cardiovascular therapeutics

    pub_type： 杂志文章

    doi：10.1111/1755-5922.12459

    authors： Jonsson A,Norberg H,Bergdahl E,Lindmark K

    更新日期：2018-10-01 00:00:00

  • Bredemolic Acid Improves Cardiovascular Function and Attenuates Endothelial Dysfunction in Diet-Induced Prediabetes: Effects on Selected Markers.

    abstract：:Prediabetes is an intermediate hyperglycaemic state which has been associated with cardiovascular dysfunction. However, cardiovascular dysfunction is not only caused by intermediate hyperglycaemia but also endothelial dysfunction, inflammation, and oxidative stress associated with prediabetes. Bredemolic acid (BA), an...

    journal_title：Cardiovascular therapeutics

    pub_type： 杂志文章

    doi：10.1155/2020/1936406

    authors： Akinnuga AM,Siboto A,Khumalo B,Sibiya NH,Ngubane P,Khathi A

    更新日期：2020-02-11 00:00:00

  • Remote physiological ischemic training promotes coronary angiogenesis via molecular and cellular mobilization after myocardial ischemia.

    abstract：AIM:This study was designed to explore the mechanism of physiological ischemic training (PIT) on remote limbs, with a special focus on the potential role of endothelial progenitor cells (EPCs), vascular endothelial growth factor (VEGF), and nitric oxide (NO) in local ischemic myocardium. METHOD:Myocardial ischemia (MI...

    journal_title：Cardiovascular therapeutics

    pub_type： 杂志文章

    doi：10.1111/1755-5922.12257

    authors： Zheng Y,Xiao M,Li L,Li J,Reinhardt JD,Lu X

    更新日期：2017-06-01 00:00:00

  • Cytochrome P450 2C9 gene polymorphism and warfarin maintenance dosage in pediatric patients: A systematic review and meta-analysis.

    abstract：AIM:To assess the effect of Cytochrome P450 2C9 (CYP2C9) gene polymorphism on pediatric warfarin maintenance dosage requirement. METHODS:A previously developed search strategy was conducted in PubMed, EMBASE, and the Cochrane Library. Eligible studies published prior to January 27, 2016, were identified and compared a...

    journal_title：Cardiovascular therapeutics

    pub_type： 杂志文章,meta分析,评审

    doi：10.1111/1755-5922.12230

    authors： Zhang J,Tian L,Huang J,Huang S,Chai T,Shen J

    更新日期：2017-02-01 00:00:00

  • Effects of the recombinant form of the natural human B-type natriuretic peptide and levosimendan on pulmonary hyperventilation and chemosensivity in heart failure.

    abstract：BACKGROUND:The origin of dyspnea in chronic heart failure (HF) is multifactorial, and excessive ventilation is thought to play a role in inducing this symptom. Chemosensivity is augmented in HF, correlates with increased pulmonary ventilation (VE), and is an adverse prognostic marker. Despite increased blood levels of ...

    journal_title：Cardiovascular therapeutics

    pub_type： 杂志文章,随机对照试验

    doi：10.1111/j.1755-5922.2011.00297.x

    authors： Bocchi EA,Moura LZ,Issa VS,Cruz F,Carvalho VO,Guimarães GV

    更新日期：2013-04-01 00:00:00

  • Clopidogrel resistance: identifying and overcoming a barrier to effective antiplatelet treatment.

    abstract：:Clopidogrel is an inhibitor of the ADP receptor P2Y12 and platelet aggregation. It is widely used for the management of atherothrombotic disease in patients who have experienced severe vascular events such as stroke or myocardial infarction or with peripheral artery disease. However, some patients show "resistance" to...

    journal_title：Cardiovascular therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1755-5922.2010.00202.x

    authors： Uchiyama S

    更新日期：2011-12-01 00:00:00

  • Stromal cell derived factor-1 (SDF-1) targeting reperfusion reduces myocardial infarction in isolated rat hearts.

    abstract：:Recent studies have shown that stromal cell derived factor-1 (SDF-1), first known as a cytokine involved in recruiting stem cells into injured organs, confers myocardial protection in myocardial infarction, which is not dependent on stem cell recruitment but related with modulation of ischemia-reperfusion (I/R) injury...

    journal_title：Cardiovascular therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1755-5922.2011.00301.x

    authors： Jang YH,Kim JH,Ban C,Ahn K,Cheong JH,Kim HH,Kim JS,Park YH,Kim J,Chun KJ,Lee GH,Kim M,Kim C,Xu Z

    更新日期：2012-10-01 00:00:00

  • Extended dual antiplatelet therapy after acute coronary syndrome in Spain: Results from the EPICOR study.

    abstract：INTRODUCTION:Real-world, country-specific studies of dual antiplatelet therapy (DAPT) duration among survivors of acute coronary syndrome (ACS) are important for improving long-term prognosis. AIMS:To investigate DAPT duration after hospital discharge for ACS in Spain. RESULTS:Data from patients enrolled in the Spani...

    journal_title：Cardiovascular therapeutics

    pub_type： 杂志文章,多中心研究

    doi：10.1111/1755-5922.12237

    authors： Bardají A,Leal M,Arrarte V,Garcia-Moll X,Pérez de Isla L,Bueno H

    更新日期：2017-04-01 00:00:00

  • The antianginal agent ranolazine is a potent antiarrhythmic agent that reduces ventricular arrhythmias: through a mechanism favoring inhibition of late sodium channel.

    abstract：BACKGROUND:The antianginal agent ranolazine (R) has shown some promise as an antiarrhythmic agent but its mechanism of action is not known. Previously, we have shown that R suppresses ventricular arrhythmias at a concentration >10 μM that may affect multiple ion currents including IKr. PURPOSE:The present study was ca...

    journal_title：Cardiovascular therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1755-5922.2010.00203.x

    authors： Kloner RA,Dow JS,Bhandari A

    更新日期：2011-08-01 00:00:00

  • Insulin resistance: a potential new target for therapy in patients with heart failure.

    abstract：:There is increasing evidence to suggest that chronic heart failure (CHF) is an insulin resistant (IR) state and that the degree of IR correlates with the severity and mortality of CHF. The pathophysiology of IR in CHF has yet to be fully defined. Additionally, it remains to be determined if IR is merely a marker refle...

    journal_title：Cardiovascular therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1755-5922.2008.00053.x

    authors： Wong AK,AlZadjali MA,Choy AM,Lang CC

    更新日期：2008-10-01 00:00:00

  • Long-Term Safety of a Coordinated Delivery Tablet of Enteric-Coated Aspirin 325 mg and Immediate-Release Omeprazole 40 mg for Secondary Cardiovascular Disease Prevention in Patients at GI Risk.

    abstract：INTRODUCTION:In two, 6-month, randomized, double-blind Phase 3 trials, PA32540 (enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg) compared to aspirin alone was associated with fewer endoscopic gastric and duodenal ulcers in patients requiring aspirin therapy for secondary cardiovascular disease (CVD...

    journal_title：Cardiovascular therapeutics

    pub_type： 杂志文章

    doi：10.1111/1755-5922.12172

    authors： Goldstein JL,Whellan DJ,Scheiman JM,Cryer BL,Eisen GM,Lanas A,Fort JG

    更新日期：2016-04-01 00:00:00

  • The "dual-pathway" strategy after acute coronary syndrome: rivaroxaban and antiplatelet agents in the ATLAS ACS 2-TIMI 51 trial.

    abstract：:Acute coronary syndrome (ACS) is a medical emergency often associated with an occlusive coronary event with consequent myocardial underperfusion. Patients require immediate antiplatelet therapy and long-term antithrombotic prophylaxis to reduce the risk of recurrence. Acetylsalicylic acid (ASA) alone or in combination...

    journal_title：Cardiovascular therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/1755-5922.12083

    authors： Cohen M,Iyer D

    更新日期：2014-10-01 00:00:00

  • Impact of Thrombocytopenia on In-Hospital Outcome in Patients Undergoing Percutaneous Coronary Intervention.

    abstract：Background:Thrombocytopenia was intuitively considered to be associated with higher risk of bleeding and multiple comorbidities after percutaneous coronary intervention (PCI). However, controversial results exist, and the real-world clinical impact of thrombocytopenia in patients undergoing PCI is largely unknown. The ...

    journal_title：Cardiovascular therapeutics

    pub_type： 杂志文章

    doi：10.1155/2021/8836450

    authors： Chen Z,Liu Z,Li N,Liu R,Wang M,Wang D,Li C,Li K,Luo F,He Y

    更新日期：2021-01-13 00:00:00

  • Fenoldopam in critically ill patients with early renal dysfunction. A crossover study.

    abstract：BACKGROUND:Acute kidney injury is a frequent problem among many critically ill patients, commonly in the context of multiple organ failure and decreased renal perfusion. Its presence conveys a poor prognosis. Currently, effective therapeutic interventions are limited and dopaminergic agonists have been suggested as an ...

    journal_title：Cardiovascular therapeutics

    pub_type： 杂志文章,随机对照试验

    doi：10.1111/j.1755-5922.2010.00217.x

    authors： Cobas M,Paparcuri G,De La Pena M,Cudemus G,Barquist E,Varon A

    更新日期：2011-08-01 00:00:00

  • Gender-related differences in antiplatelet treatment patterns and outcome: Insights from the GReekAntiPlatElet Registry.

    abstract：AIMS:Data on the clinical impact of gender in "real-life" patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), receiving clopidogrel, prasugrel, or ticagrelor are limited. We aimed to investigate sex-based differences in clinical outcome of those patients. METHODS:In a prosp...

    journal_title：Cardiovascular therapeutics

    pub_type： 杂志文章,多中心研究

    doi：10.1111/1755-5922.12270

    authors： Xanthopoulou I,Davlouros P,Deftereos S,Hamilos M,Sitafidis G,Kanakakis I,Vavouranakis M,Goudevenos J,Lekakis J,Alexopoulos D

    更新日期：2017-08-01 00:00:00

  • Pharmacological profile of the selective mitochondrial F1F0 ATP hydrolase inhibitor BMS-199264 in myocardial ischemia.

    abstract：:The mitochondrial F1F0 ATP synthase is responsible for the majority of ATP production in mammals and does this through a rotary catalytic mechanism. Studies show that the F1F0 ATP synthase can switch to an ATP hydrolase, and this occurs under conditions seen during myocardial ischemia. This ATP hydrolysis causes wasti...

    journal_title：Cardiovascular therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1755-5922.2008.00065.x

    authors： Grover GJ,Malm J

    更新日期：2008-01-01 00:00:00

  • TREK-1 K(+) channels in the cardiovascular system: their significance and potential as a therapeutic target.

    abstract：:Potassium (K(+) ) channels are important in cardiovascular disease both as drug targets and as a cause of underlying pathology. Voltage-dependent K(+) (K(V) ) channels are inhibited by the class III antiarrhythmic agents. Certain vasodilators work by opening K(+) channels in vascular smooth muscle cells (VSMCs), and...

    journal_title：Cardiovascular therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1755-5922.2010.00227.x

    authors： Goonetilleke L,Quayle J

    更新日期：2012-02-01 00:00:00

  • Diagnosis and management of atrial fibrillation: an overview.

    abstract：:Atrial fibrillation (AF) has been defined as the new cardiovascular "epidemic". Its prevalence is rising in developed countries, and the associated social and economic costs are high. In the last few years, there has been an increasing interest in understanding the mechanisms of AF and its management. New pharmacother...

    journal_title：Cardiovascular therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/1755-5922.12090

    authors： Romero I,Nedios S,Kriatselis C

    更新日期：2014-10-01 00:00:00

  • Combating Donor Organ Shortage: Organ Care System Prolonging Organ Storage Time and Improving the Outcome of Heart Transplantations.

    abstract：Introduction:Cardiovascular diseases are the number one cause of death globally contributing to 37% of all global deaths. A common complication of cardiovascular disease is heart failure, where, in such cases, the only solution would be to conduct a heart transplant. Every 10 minutes a new patient is added to the trans...

    journal_title：Cardiovascular therapeutics

    pub_type： 杂志文章,评审

    doi：10.1155/2019/9482797

    authors： Sunjaya AF,Sunjaya AP

    更新日期：2019-04-01 00:00:00

  • New Clinical Classification for Ventricular Free Wall Rupture following Acute Myocardial Infarction.

    abstract：:Ventricular free wall rupture (FWR) is a catastrophic complication after acute myocardial infarction (AMI). However, patients with FWR die of cardiac tamponade secondary to intrapericardial hemorrhage that can be treated if properly diagnosed. Unfortunately, FWR was still not diagnosed and classified quickly and accur...

    journal_title：Cardiovascular therapeutics

    pub_type： 杂志文章

    doi：10.1155/2021/1716546

    authors： Gong W,Nie S

    更新日期：2021-01-02 00:00:00

  • Sulforaphane protection against the development of doxorubicin-induced chronic heart failure is associated with Nrf2 Upregulation.

    abstract：BACKGROUND:Doxorubicin (DOX) is an anthracycline antitumor drug. However, its clinical use is limited by dose-dependent cardiotoxicity and even progresses to chronic heart failure (CHF). OBJECTIVE:This study aims to investigate whether the Nrf2 activator, sulforaphane (SFN), can prevent DOX-induced CHF. METHODS:Male ...

    journal_title：Cardiovascular therapeutics

    pub_type： 杂志文章

    doi：10.1111/1755-5922.12277

    authors： Bai Y,Chen Q,Sun YP,Wang X,Lv L,Zhang LP,Liu JS,Zhao S,Wang XL

    更新日期：2017-10-01 00:00:00

  • Cell-based therapy for chronic ischemic heart disease--a clinical perspective.

    abstract：:In patients with ischemic heart disease, the goal of cell therapy is to improve perfusion and function of the damaged heart muscle. For this review, we selected articles that reported the findings from the major clinical studies of cardiovascular stem cell therapy in patients with chronic ischemic heart disease. Becau...

    journal_title：Cardiovascular therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1755-5922.2010.00214.x

    authors： Perin EC,Silva GV

    更新日期：2011-06-01 00:00:00

  • The Relation between Volume and Outcome of Transcatheter and Surgical Aortic Valve Replacement: A Systematic Review and Meta-Analysis.

    abstract：:Transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) are standard procedures for dealing with severe aortic stenosis patients. Researchers have not carried out a systematic review of the volume-outcome relationship in TAVR and SAVR. Our study is intended to address this problem. W...

    journal_title：Cardiovascular therapeutics

    pub_type： 杂志文章,meta分析

    doi：10.1155/2020/2601340

    authors： He J,Zhang Z,Wang H,Cai L

    更新日期：2020-04-18 00:00:00

  • Metformin and its effects on myocardial dimension and left ventricular hypertrophy in normotensive patients with coronary heart disease (the MET-REMODEL study): rationale and design of the MET-REMODEL study.

    abstract：:Left ventricular hypertrophy (LVH) is a common and independent risk factor for cardiovascular events in patients with coronary artery disease (CAD). Controlling blood pressure is the standard approach to the management of LVH, but this is only partially effective as LVH also persists in normotensive patients. Apart fr...

    journal_title：Cardiovascular therapeutics

    pub_type： 杂志文章,随机对照试验

    doi：10.1111/1755-5922.12101

    authors： Mohan M,McSwiggan S,Baig F,Rutherford L,Lang CC

    更新日期：2015-02-01 00:00:00